| Primary |
| Benign Prostatic Hyperplasia |
54.0% |
| Drug Use For Unknown Indication |
22.6% |
| Product Used For Unknown Indication |
9.7% |
| Prostatomegaly |
3.3% |
| Prostatic Disorder |
1.9% |
| Hypertension |
1.6% |
| Prostate Cancer |
0.9% |
| Micturition Disorder |
0.9% |
| Alopecia |
0.8% |
| Prostatic Adenoma |
0.7% |
| Accidental Exposure |
0.6% |
| Atrial Fibrillation |
0.4% |
| Blood Cholesterol Increased |
0.4% |
| Glaucoma |
0.4% |
| Ill-defined Disorder |
0.3% |
| Nocturia |
0.3% |
| Prophylaxis |
0.3% |
| Prostatitis |
0.3% |
| Urinary Tract Disorder |
0.3% |
| Depression |
0.3% |
|
| Drug Ineffective |
20.5% |
| Gynaecomastia |
7.4% |
| Breast Tenderness |
5.9% |
| Prostatic Specific Antigen Increased |
5.8% |
| Semen Volume Decreased |
5.8% |
| Rash |
5.2% |
| Erectile Dysfunction |
5.2% |
| Pollakiuria |
5.2% |
| Urine Flow Decreased |
4.6% |
| Libido Decreased |
4.2% |
| Product Quality Issue |
3.9% |
| Death |
3.6% |
| Nipple Pain |
3.3% |
| Breast Enlargement |
3.0% |
| Nocturia |
3.0% |
| Urinary Retention |
2.9% |
| Sexual Dysfunction |
2.8% |
| Therapeutic Response Unexpected |
2.7% |
| Prostate Cancer |
2.5% |
| Dizziness |
2.4% |
|
| Secondary |
| Benign Prostatic Hyperplasia |
25.9% |
| Product Used For Unknown Indication |
24.1% |
| Drug Use For Unknown Indication |
10.8% |
| Hypertension |
6.5% |
| Prostatomegaly |
4.0% |
| Alopecia |
3.7% |
| Blood Pressure Abnormal |
3.1% |
| Prostatic Disorder |
3.1% |
| Chronic Obstructive Pulmonary Disease |
2.7% |
| Depression |
2.7% |
| Cardiac Disorder |
1.6% |
| Micturition Disorder |
1.6% |
| Type 2 Diabetes Mellitus |
1.6% |
| Blood Cholesterol Increased |
1.5% |
| Dementia |
1.5% |
| Respiratory Tract Infection |
1.3% |
| Atrial Fibrillation |
1.2% |
| Amnesia |
1.0% |
| Anxiety |
1.0% |
| Diabetes Mellitus |
1.0% |
|
| Urine Flow Decreased |
11.3% |
| Death |
7.8% |
| Drug Ineffective |
7.8% |
| Eczema |
7.8% |
| Dizziness |
7.0% |
| Thrombocytopenia |
6.1% |
| Pollakiuria |
5.2% |
| Jaundice |
4.3% |
| Pneumonia |
4.3% |
| Restlessness |
4.3% |
| Weight Increased |
4.3% |
| White Blood Cell Count Increased |
4.3% |
| Anaemia Haemolytic Autoimmune |
3.5% |
| Neoplasm Malignant |
3.5% |
| Renal Failure |
3.5% |
| Skin Atrophy |
3.5% |
| Vitamin D Decreased |
3.5% |
| Abdominal Discomfort |
2.6% |
| Aggression |
2.6% |
| Angina Pectoris |
2.6% |
|
| Concomitant |
| Product Used For Unknown Indication |
29.8% |
| Drug Use For Unknown Indication |
13.6% |
| Hypertension |
9.0% |
| Benign Prostatic Hyperplasia |
7.2% |
| Atrial Fibrillation |
4.3% |
| Prostatomegaly |
3.9% |
| Blood Cholesterol Increased |
3.6% |
| Diabetes Mellitus |
3.1% |
| Prostatic Disorder |
3.0% |
| Multiple Myeloma |
2.9% |
| Type 2 Diabetes Mellitus |
2.4% |
| Pain |
2.4% |
| Prophylaxis |
2.4% |
| Depression |
2.1% |
| Gastrooesophageal Reflux Disease |
2.1% |
| Chronic Obstructive Pulmonary Disease |
2.0% |
| Cardiac Disorder |
2.0% |
| Prostate Cancer |
1.9% |
| Scleroderma |
1.2% |
| Blood Pressure |
1.1% |
|
| Weight Decreased |
13.9% |
| Drug Ineffective |
8.7% |
| Death |
8.1% |
| Rash |
5.4% |
| Syncope |
5.0% |
| Flushing |
4.8% |
| Urinary Tract Infection |
4.6% |
| Vision Blurred |
4.5% |
| Weight Increased |
4.5% |
| Pneumonia |
4.4% |
| Pruritus |
4.4% |
| Pyrexia |
4.1% |
| Renal Failure |
3.8% |
| Oedema Peripheral |
3.6% |
| Vomiting |
3.6% |
| Dizziness |
3.4% |
| Diarrhoea |
3.3% |
| Nausea |
3.3% |
| Renal Failure Acute |
3.3% |
| White Blood Cell Count Decreased |
3.3% |
|
| Interacting |
| Drug Use For Unknown Indication |
60.0% |
| Blood Cholesterol |
20.0% |
| Prostatic Specific Antigen |
20.0% |
|
| Drug Interaction |
33.3% |
| Impaired Driving Ability |
33.3% |
| Myalgia |
33.3% |
|
